Clinical trials: Discharge Time
Pain, Postoperative
An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery
The purpose of this study is to evaluate the mobilization characteristics, clinical use, safety and Ease of Care (EOC) of a fentanyl Iontophoretic Transdermal Patient Controlled Analgesia (PCA) system (Ionsys) and morphine…
- Trial name
- NCT00766506
- Testing
- Fentanyl IONSYS, Morphine IV PCA
- Where
- 7 sites in United Kingdom
- Volunteers
- 108 people
- Sponsor
- Janssen-Cilag Ltd.
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
This is a multicenter study evaluating the safety and tolerability of increasing doses of Toca 511, a retroviral replicating vector, injected into the resection cavity of patients with Grade III or Grade IV Gliomas who have…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01470794
- Testing
- Toca 511 vector, Toca FC
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Tocagen Inc.
Low Back Pain
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
This is a 6-month, nonrandomized, open-label extension study to assess the long-term safety of hydrocodone bitartrate extended-release (ER) tablets in patients with moderate to severe chronic low back pain who require continuous…
- Trial name
- NCT01922739
- Testing
- Hydrocodone ER
- Where
- 61 sites in United States
- Volunteers
- 182 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
COPD
Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
The study is an observational multicenter descriptive study. It is planned to enroll approximately 1250 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or…
- Trial name
- CLOUD (NCT02346292)
- Where
- 30 sites in Russia
- Volunteers
- 1,250 people
- Sponsor
- AstraZeneca
Healthy
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)
The objective of this study was to compare the pharmacokinetic profiles of the test product, 300 mg trazodone hydrochloride (HCl) extended-release caplets (containing Contramid®), when administered as a single dose, and the…
- Trial name
- NCT01121900
- Testing
- Trazodone HCl
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Labopharm Inc.
Neuropathy;Peripheral
Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial
A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.
- Trial name
- SELECT (NCT05980767)
- Testing
- Temporary Peripheral Nerve Stimulation System
- Where
- 2 sites in Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Epineuron Technologies Inc.
Low Back Pain
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain
The primary objective of this study is to evaluate the efficacy of hydrocodone bitartrate extended-release tablets at doses of 30 to 90 mg every 12 hours compared with placebo in alleviating moderate to severe pain in patients…
- Trial name
- NCT01789970
- Testing
- Hydrocodone ER
- Where
- 87 sites in United States
- Volunteers
- 625 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Attention Deficit Hyperactivity Disorder
The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
This study was designed to compare Concerta Extended Release tablets with Metadate CD capsules in children with ADHD who were between 6 and 12 years old.
- Trial name
- NCT00381758
- Testing
- Methylphenidate Extended Release Capsules
- Volunteers
- 184 people
- Sponsor
- UCB Pharma
Chorea
First Time Use of SD-809 in Huntington Disease
The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
- Trial name
- First-HD (NCT01795859)
- Testing
- SD-809
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 90 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Healthy
Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
The primary purpose of this study was to evaluate the effect of meloxicam tablets (7.5, 15 mg and 30 mg) with meloxicam placebo.
- Trial name
- NCT02183155
- Testing
- Meloxicam - low, Meloxicam - medium, Meloxicam - high
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)
This study is multicenter, Ph IV, single arm, interventional study to assess relative reduction of morning stiffness of Lodotra® in Rheumatoid Arthritis patients.Study medication will start after study visit at baseline (week 0…
- Trial name
- NCT02072200
- Testing
- Lodotra®
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Mundipharma Korea Ltd
Preterm Birth
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
Assess the efficacy of 2 Cervical Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous birth before gestation weeks 32 (31 weeks and 6 days) and 34…
- Trial name
- PCP002 (NCT02225353)
- Testing
- Progesterone Cervical Pessary 6.3 g, Progesterone 200 mg vaginal capsules, Progesterone Cervical Pessary 7.7 g
- Where
- 4 sites in Chile
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Type 2 Diabetes Mellitus
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy…
- Trial name
- NCT00637273
- Testing
- exenatide once weekly, sitagliptin, pioglitazone
- Where
- 62 sites in United States, India and 1 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Schizophrenia
Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) in symptomatic participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Trial name
- NCT01362439
- Testing
- Paliperidone ER
- Volunteers
- 133 people
- Sponsor
- Janssen-Cilag S.p.A.
Chronic Pain, Postsurgical Pain
Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children
The purpose of this study was to assess the safety and pharmacokinetics (single- and multiple-dose) of oxymorphone ER for the relief of moderate to severe pain in pediatric participants ages 7 - ≤17 years old requiring a…
- Trial name
- NCT04681027
- Testing
- Oxymorphone hydrochloride (HCl)
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Healthy
Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers
The purpose of this study is to 1) evaluate the extent of absorption of a single dose of a pregabalin controlled release (CR) tablet administered a) fasted at bedtime, b) immediately following a 400 to 500 calorie evening meal…
- Trial name
- NCT01291524
- Testing
- Pregabalin controlled release, 330 mg, 400 to 500 calorie, Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, bedtime
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Rheumatoid Arthritis
Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers
This study is to test the idea that a controlled release formulation of CE-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.
- Trial name
- NCT00782600
- Testing
- suspension IR, CR 1, CR 2
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Impotence
Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction
Assessment of duration of action, safety \& toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction.
- Trial name
- NCT00174486
- Testing
- UK0369,003, Cialis (Tadalafil)
- Volunteers
- 300 people
- Sponsor
- Pfizer
Dysglycemia
Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia
Patients who have experienced dysglycemia in hospital (either from diabetes, post-solid organ transplantation, medication titration, or other causes) may struggle to manage their blood glucose when discharged home.
- Trial name
- DIREMOS (NCT05746286)
- Testing
- Dexcom G6 CGM
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- DexCom, Inc.